Praktické lekárnictvo 2-3/2014

Pharmacotherapy of inflammatory rheumatic diseases

Inflammatory rheumatic diseases according to the Decker classification are included in the groups of diffuse connective tissue diseases, spondylarthrit is and arthritis associated with the presence of an infections agens. The primary place of pathological inflammation is the synovial tissue, the main clinical sign is arthritis. The aim of pharmacotherapy is to affect the inflammatory and immune pathological processes to achieving remission or at least decreasing the laboratory and clinical disease activity, preventing radiological and functional changes in affected joint sand thus formatting of disability patients. Such disease-modifying effect have the basal drugs, synthetic (DMARD: methorexate, sulfasalazine, antimalarics, leflunomide) and biological (etanercept, infliximab, adalimumab, golimumab, certolizumab pegol, rituximab, abatacept, tocilizumab, anakinra, belimumab, ustekinumab). Since their effect appear after weeks or months of treatment, there are combined with nonsteroidal antiphlogistics and glucocorticoids asymptomatically acting drugs. Knowledge of pharmacotherapies treatment of rheumatic diseases pharmacist issuing medication to a patient, help increase patient compliance to treatment and the possibility of more frequent consultations as a doctor helps the patient also mentally learn fully valuable live with their disease and her treatment.

Keywords: rheumatic diseases, nonsteroidal antiphlogistics, glucocorticoids, disease modifying antirheumatic drugs, biological therapy.